+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Acute Renal Failure Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • PDF Icon

    Report

  • 130 Pages
  • May 2024
  • Region: Global
  • IMARC Group
  • ID: 5970114
The 7 major acute renal failure markets are expected to exhibit a CAGR of 4.06% during 2023-2034.

The acute renal failure market has been comprehensively analyzed in this report titled "Acute Renal Failure Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acute renal failure is a medical condition characterized by a sudden and rapid decline in kidney processes. In this disease, the kidneys are unable to perform their function properly, leading to a buildup of waste products and harmful fluids in the body. The indications of the ailment include decreased or no urine output, swelling in the legs, ankles, or face, fluid retention, fatigue, weakness, altered mental status, lethargy, nausea, vomiting, loss of appetite, confusion, difficulty concentrating, shortness of breath, chest pain or pressure, irregular heartbeat, abdominal discomfort, etc. The diagnosis of acute renal failure typically involves a combination of medical history evaluation, physical examination, and laboratory tests. The healthcare provider will initially assess the levels of blood urea nitrogen (BUN) and creatinine in the blood. In some cases, various imaging studies, such as ultrasounds, computed tomography scans, magnetic resonance imaging, etc., are also utilized to evaluate the structure and condition of the kidneys and urinary tract. These tests can help in identifying any obstructions or abnormalities in patients and rule out other possible diseases.

The increasing incidences of severe dehydration, low blood pressure, infections, etc., which lead to reduced blood flow to the kidneys, are primarily driving the acute renal failure market. In addition to this, the rising cases of blockages in the urinary tract, like kidney stones or an enlarged prostate, that can obstruct urine flow and cause renal damage are also creating a positive outlook for the market. Moreover, the widespread adoption of effective drugs, including diuretics and angiotensin-converting enzyme inhibitors, to control blood pressure and relieve fluid overload in the body, is further bolstering the market growth. Apart from this, the escalating application of continuous renal replacement therapy, since it offers continuous clearance of solutes and toxins from the blood, thereby allowing better control of uremia and metabolic disturbances associated with the ailment, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of erythropoiesis-stimulating agents, which effectively enhance red blood cell production and help in alleviating disease symptoms, is expected to drive the acute renal failure market during the forecast period.

This report provides an exhaustive analysis of the acute renal failure market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acute renal failure and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acute renal failure market in any manner.

Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the acute renal failure market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the acute renal failure market

Competitive Landscape:

This report also provides a detailed analysis of the current acute renal failure marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

  • How has the acute renal failure market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the acute renal failure market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the acute renal failure market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?

Epidemiology Insights

  • What is the number of prevalent cases (2018-2034) of acute renal failure across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of acute renal failure by age across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of acute renal failure by gender across the seven major markets?
  • How many patients are diagnosed (2018-2034) with acute renal failure across the seven major markets?
  • What is the size of the acute renal failure patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of acute renal failure?
  • What will be the growth rate of patients across the seven major markets?

Acute Renal Failure: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for acute renal failure drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acute renal failure market?
  • What are the key regulatory events related to the acute renal failure market?
  • What is the structure of clinical trial landscape by status related to the acute renal failure market?
  • What is the structure of clinical trial landscape by phase related to the acute renal failure market?
  • What is the structure of clinical trial landscape by route of administration related to the acute renal failure market?
This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Acute Renal Failure - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 Acute Renal Failure - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Acute Renal Failure - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 Acute Renal Failure - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Acute Renal Failure - Unmet Needs10 Acute Renal Failure - Key Endpoints of Treatment
11 Acute Renal Failure - Marketed Products
11.1 List of Acute Renal Failure Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 Acute Renal Failure - Pipeline Drugs
12.1 List of Acute Renal Failure Pipeline Drugs Across the Top 7 Markets
12.1.1 TIN816 - Novartis Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 RMC 035 - Guard Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 SBI 101 - Sentien Biotechnologies
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 recAP - AM-Pharma Holding
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 ANG-3777 - Angion Biomedica
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. Acute Renal Failure - Attribute Analysis of Key Marketed and Pipeline Drugs
14. Acute Renal Failure - Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Acute Renal Failure - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Acute Renal Failure - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Acute Renal Failure - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Acute Renal Failure - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Acute Renal Failure - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Acute Renal Failure - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Acute Renal Failure - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Acute Renal Failure - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Acute Renal Failure - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Acute Renal Failure - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Acute Renal Failure - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Acute Renal Failure - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Acute Renal Failure - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Acute Renal Failure - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Acute Renal Failure - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Acute Renal Failure - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Acute Renal Failure - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Acute Renal Failure - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Acute Renal Failure - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Acute Renal Failure - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Acute Renal Failure - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Acute Renal Failure - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Acute Renal Failure - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Acute Renal Failure - Access and Reimbursement Overview
16 Acute Renal Failure - Recent Events and Inputs From Key Opinion Leaders
17 Acute Renal Failure Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Acute Renal Failure Market - Strategic Recommendations19 Appendix

Methodology

Loading
LOADING...